Research Focus

Former Employee. Medicine; Research Stdy Asst II

Recent additions – View all

1. A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC)

   Meeting Abstract

   Segal, N. H.; Verghis, J.; Govindan, S.; Maliakal, P.; Sharkey, R. M.; Wegener, W. A.; Goldenberg, D. M.; Saltz, L. B.
   Cancer Research (2013)

   Fulltext@MSK | Save
2. Initial results of a new antibody-drug conjugate (ADC), IMMU-130 (labetuzumab-SN38), in patients with metastatic colorectal cancer (mCRC)

   Meeting Abstract

   Segal, N. H.; Verghis, J.; Govindan, S.; Maliakal, P.; Sharkey, R. M.; Wegener, W. A.; Goldenberg, D. M.; Saltz, L. B.
   European Journal of Cancer (2013)

   Fulltext@MSK | Save